Buprenorphine Dosing Interval - 5 - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Buprenorphine Dosing Interval - 5

This study has been completed.

Study NCT00000209. Last updated on August 16, 2005. Information provided by National Institute on Drug Abuse (NIDA)

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

Buprenorphine Dosing Interval - 5

Official Title ^†

Buprenorphine Dosing Interval

Brief Summary

The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.

Detailed Description

Study Phase

Phase II

Study Type ^†

Interventional

Study Design ^†

Treatment, Single Blind, Placebo Control

Primary Outcome Measure ^†

Drug use
Withdrawal symptoms
Opiate and cocaine craving

Secondary Outcome Measure ^†

Condition ^†

Opioid-Related Disorders

Intervention ^†

Drug: Buprenorphine

MEDLINE PMIDs

Links

Recruitment Information Fields

Recruitment Status ^†

Completed

Enrollment ^†

Start Date ^†

November 1992

Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Gender

Both

Ages

21 Years to 50 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Administrative Information Fields

NCT ID ^†

NCT00000209

Organization ID

NIDA-06082-5

Secondary IDs ^††

R18-06082-5

Study Sponsor ^†

National Institute on Drug Abuse (NIDA)

Collaborators ^††

Investigators ^†

Principal Investigator:

Walter Ling, M.D.

Friends Research Institute, Inc.

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

September 1994

First Received Date ^†

September 20, 1999

Last Updated Date

August 16, 2005

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.